Monoclonal Antibodies and Immunotoxins in Bone Marrow Transplantation: Purging Marrow of ALL or GVHD Cells with Preservation of Stem Cells
Bone marrow transplantation is now in frequent use for the treatment of a number of hematologic diseases, including severe immune deficiencies, aplastic anemias, and acute and chronic leukemias. In allogeneic transplantation, a problem remains with graft versus host disease-producing immunocompetent cells which contaminate the marrow. In autologous transplantation for treatment of the leukemias, residual leukemic cells may result in the return of unwanted cells to the recipient. Thus, an objective for both autologous and allogeneic marrow transplantation has become the removal of these unwanted cells prior to infusion into the recipient.
KeywordsBone Marrow Transplantation Aplastic Anemia Chronic Leukemia Allogeneic Marrow Unwanted Cell
Unable to display preview. Download preview PDF.
- 1.Filipovich AH, Ramsay NKC, Warkentin P, McGlave PB, Goldstein G, Kersey JH (1982) Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone marrow transplantation. Lancet 1 /8284: 1266–1269PubMedCrossRefGoogle Scholar
- 2.LeBien TW, Ash RC, Zanjani ED, Kersey JH (1983) In vitro destruction of leukemic cells using a cocktail of monoclonal antibodies. In: Neth R (ed) Modern trends in human leukemia V. Springer, Berlin Heidelberg New York, pp 112–115Google Scholar
- 5.U.S. Patent No 4,539, 457, Anti-thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant. Neville DM Jr, Youle RJ U.S. Patent No 4,440,747, Monoclonal antibody- ricin as a treatment of animal graft versus host disease. Neville DM Jr, Youle RJGoogle Scholar
- 8.Vallera DA, Soderling CCB, Carlson GJ, Kersey JH (1981) Bone marrow transplantation across major histocompatibility barriers in mice: the effect of elimination of T cells from donor grafts by treatment with monoclonal thy 1.2 plus complement or antibody alone. Transplantation 31: 218–222PubMedCrossRefGoogle Scholar
- 9.Vallera DA, Youle RJ, Neville DM Jr, Kersey JH (1982) Bone marrow transplantation across major histocompatibility barriers V. Protection of mice from lethal GVHD by pretreatment of donor cells with monoclonal anti-thy 1.2 coupled to the toxin lectin ricin. J Exp Med 155: 949–954PubMedCrossRefGoogle Scholar
- 10.Youle RJ, Neville DM Jr (1979) Receptormediated transport of the hybrid protein ricin-diphtheria toxin fragment A with subsequent ADP-ribosylation of intracellular elongation factor II. J Biol Chem 24: 11089Google Scholar
- 14.Beverley PCL, Callard RE (1981) Distinctive functional characteristics of human T lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody. Eur J Immunol 11: 329Google Scholar
- 15.Royston I, Majda A, Baird SM, Meserve BL, Griffiths JC (1979) Monoclonal antibody specific for human T lymphocyte-identification of normal and malignant T-cells. Blood 54: 1069Google Scholar
- 17.Stong RC, Youle RJ, Vallera DA (1984) Elimination of clonogenic T-leukemic cells from human bone marrow using anti-Mr 65 000 protein immunotoxins. Cancer Res 4: 3000–3006Google Scholar
- 18.Korsmeyer SJ, Arnold A, Bakhshi A, Ravetch JV, Siebenlist U, Hieter PA, Sharrow SO, LeBien TW, Kersey JH, Poplack DG, Leder P, Waldmann TA (1983) Immunoglobulin gene rearrangement and cell surface antigen expression in acute lympho-cytic leukemias of T cell and B cell precursor origins. J Clin Invest 71: 301–313PubMedCrossRefGoogle Scholar
- 20.Kersey JH, LeBien TW, Abramson CS, Newman R, Sutherland R, Greaves M (1981) p24: a human leukemia-associated and lymphohemopoietic progenitor cell surface structure identified with monoclonal antibody. J Exp Med 153: 726–731Google Scholar
- 22.LeBien TW, Stepan DE, Bartholomew RM, Stong RC, Anderson JM (1985) Utilization of a colony assay to assess the variables influencing elimination of leukemic cells from human bone marrow with monoclonal antibodies and complement. Blood (in press)Google Scholar